DelfaGLP-1 Atlas

Lead sponsor

Viking Therapeutics, Inc.

5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

5

Trials led

2

Active

6,148

Total enrollment

148

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
1
Phase 2
2
Phase 3
2

Trials by status

Active, not recruiting
2
Completed
3

Trials led

VANQUISH 1BMI ≥30Ph 3Active, not recruiting4,500
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)BMI ≥27Ph 3Active, not recruiting1,100
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)BMI ≥30Ph 2Completed280
VENTUREBMI ≥30Ph 2Completed176
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735Healthy volunteersPh 1Completed92